Positive News SentimentPositive NewsNASDAQ:CTXR Citius Pharmaceuticals (CTXR) Stock Price, News & Analysis $1.38 -0.09 (-5.78%) As of 03:19 PM Eastern This is a fair market value price provided by Polygon.io. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsHeadlinesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock About Citius Pharmaceuticals Stock (NASDAQ:CTXR) 30 days 90 days 365 days Advanced Chart View Price History Chart DataSkip Price History Chart Get Citius Pharmaceuticals alerts:Sign Up Key Stats Today's Range$1.38▼$1.4750-Day Range$0.68▼$2.2052-Week Range$0.65▼$26.25Volume384,321 shsAverage Volume1.29 million shsMarket Capitalization$14.72 millionP/E RatioN/ADividend YieldN/APrice Target$53.00Consensus RatingModerate Buy Company Overview Citius Pharmaceuticals, Inc., a late-stage pharmaceutical company, engages in the development and commercialization of critical care products focusing on oncology products, anti-infectives products in adjunct cancer care, prescription products, and stem cell therapy. It is developing five proprietary products comprising LYMPHIR, an engineered IL-2 diphtheria toxin fusion protein for the treatment of patients with persistent or recurrent cutaneous T-cell lymphoma, which is in Phase 3 clinical trial; Mino-Lok, an antibiotic lock solution to treat patients with catheter-related bloodstream infections by salvaging the infected catheter, which is in Phase 3 clinical trial; Halo-Lido, a corticosteroid-lidocaine topical formulation that intends to provide anti-inflammatory and anesthetic relief to persons suffering from hemorrhoids that is in clinical Phase 2b trial; Mino-Wrap, a liquifying gel-based wrap for reduction of tissue expander infections following breast reconstructive surgeries; and NoveCite, a mesenchymal stem cell therapy for the treatment of acute respiratory disease syndrome. The company was founded in 2007 and is headquartered in Cranford, New Jersey. Read More Citius Pharmaceuticals Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks62nd Percentile Overall ScoreCTXR MarketRank™: Citius Pharmaceuticals scored higher than 62% of companies evaluated by MarketBeat, and ranked 415th out of 935 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion3.3 / 5Analyst RatingModerate Buy Consensus RatingCitius Pharmaceuticals has received a consensus rating of Moderate Buy. The company's average rating score is 2.50, and is based on 2 buy ratings, 2 hold ratings, and no sell ratings.Amount of Analyst CoverageCitius Pharmaceuticals has only been the subject of 3 research reports in the past 90 days.Read more about Citius Pharmaceuticals' stock forecast and price target. Earnings and Valuation1.3 / 5Proj. Earnings GrowthGrowing Earnings GrowthEarnings for Citius Pharmaceuticals are expected to grow in the coming year, from ($4.50) to $1.25 per share.Price to Book Value per Share RatioCitius Pharmaceuticals has a P/B Ratio of 0.14. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities.Read more about Citius Pharmaceuticals' valuation and earnings. Short Interest4.0 / 5Short Interest LevelHealthy Percentage of Shares Shorted9.21% of the float of Citius Pharmaceuticals has been sold short.Short Interest Ratio / Days to CoverCitius Pharmaceuticals has a short interest ratio ("days to cover") of 0.4, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Citius Pharmaceuticals has recently decreased by 28.17%, indicating that investor sentiment is improving significantly. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldCitius Pharmaceuticals does not currently pay a dividend.Dividend GrowthCitius Pharmaceuticals does not have a long track record of dividend growth. Sustainability and ESGN/AEnvironmental ScoreN/A Percentage of Shares Shorted9.21% of the float of Citius Pharmaceuticals has been sold short.Short Interest Ratio / Days to CoverCitius Pharmaceuticals has a short interest ratio ("days to cover") of 0.4, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Citius Pharmaceuticals has recently decreased by 28.17%, indicating that investor sentiment is improving significantly. News and Social Media3.3 / 5News SentimentN/A News SentimentCitius Pharmaceuticals has a news sentiment score of 1.89. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 1.04 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 1 news article for Citius Pharmaceuticals this week, compared to 1 article on an average week.Search InterestOnly 9 people have searched for CTXR on MarketBeat in the last 30 days. This is a decrease of 0% compared to the previous 30 days.MarketBeat Follows10 people have added Citius Pharmaceuticals to their MarketBeat watchlist in the last 30 days. This is an increase of 400% compared to the previous 30 days. Company Ownership0.8 / 5Insider TradingN/A Insider Buying vs. Insider SellingIn the past three months, Citius Pharmaceuticals insiders have not sold or bought any company stock.Percentage Held by Insiders10.70% of the stock of Citius Pharmaceuticals is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by InstitutionsOnly 16.88% of the stock of Citius Pharmaceuticals is held by institutions.Read more about Citius Pharmaceuticals' insider trading history. Receive CTXR Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Citius Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter. Email Address CTXR Stock News HeadlinesCitius Oncology Announces Closing of $9.0 Million Public OfferingJuly 17, 2025 | prnewswire.comCitius Oncology Announces Pricing of $9.0 Million Public OfferingJuly 16, 2025 | prnewswire.comEx-Hedge Fund Manager Uncovers $100 Trillion Land ShiftTrump's Radical New Plan Could Enrich Thousands This isn't a campaign stunt. It's a $100 trillion move to unlock federal lands, oil reserves, and buried minerals... all for profit. Trump's team is already executing the orders... and Wall Street legend Whitney Tilson is stepping forward to show you how to position before the deadline.July 30 at 2:00 AM | Stansberry Research (Ad)Citius Oncology stock rises after expanding LYMPHIR distribution networkJuly 15, 2025 | investing.comCitius Oncology Expands Distribution Network for LYMPHIR with Execution of Distribution Services Agreement with CencoraJuly 15, 2025 | prnewswire.comCTXR - Citius Pharmaceuticals Inc Ownership - MorningstarJuly 11, 2025 | morningstar.comMCitius Pharmaceuticals, Inc.: Citius Pharmaceuticals Regains Compliance with Nasdaq Minimum Bid Price RequirementJuly 8, 2025 | finanznachrichten.deCitius Pharmaceuticals Inc (CTXR) - Investing.comJuly 8, 2025 | investing.comSee More Headlines CTXR Stock Analysis - Frequently Asked Questions How have CTXR shares performed this year? Citius Pharmaceuticals' stock was trading at $4.00 at the start of the year. Since then, CTXR shares have decreased by 63.9% and is now trading at $1.4440. How were Citius Pharmaceuticals' earnings last quarter? Citius Pharmaceuticals, Inc. (NASDAQ:CTXR) posted its quarterly earnings data on Wednesday, May, 14th. The company reported ($1.27) EPS for the quarter, missing the consensus estimate of ($1.08) by $0.19. When did Citius Pharmaceuticals' stock split? Shares of Citius Pharmaceuticals reverse split on Tuesday, November 26th 2024.The 1-25 reverse split was announced on Friday, November 22nd 2024. The number of shares owned by shareholders was adjusted after the closing bell on Monday, November 25th 2024. An investor that had 100 shares of stock prior to the reverse split would have 4 shares after the split. How do I buy shares of Citius Pharmaceuticals? Shares of CTXR stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of Citius Pharmaceuticals own? Based on aggregate information from My MarketBeat watchlists, some other companies that Citius Pharmaceuticals investors own include Waste Connections (WCN), American Water Works (AWK), The RMR Group (RMR), Voyager Therapeutics (VYGR), AU Optronics (AUOTY), DiamondRock Hospitality (DRH) and iShares Micro-Cap ETF (IWC). Company Calendar Last Earnings5/14/2025Today7/30/2025Next Earnings (Estimated)8/11/2025Fiscal Year End9/30/2025Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry MED - DRUGS Sub-IndustryPharmaceutical Products Current SymbolNASDAQ:CTXR CIK1506251 Webwww.citiuspharma.com Phone(908) 967-6677FaxN/AEmployees20Year FoundedN/APrice Target and Rating Average Price Target for Citius Pharmaceuticals$53.00 High Price Target$100.00 Low Price Target$6.00 Potential Upside/Downside+3,505.4%Consensus RatingModerate Buy Rating Score (0-4)2.50 Research Coverage4 Analysts Profitability EPS (Trailing Twelve Months)N/A Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income-$39.14 million Net MarginsN/A Pretax MarginN/A Return on Equity-58.63% Return on Assets-37.67% Debt Debt-to-Equity RatioN/A Current Ratio0.37 Quick Ratio0.06 Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value$10.25 per share Price / Book0.14Miscellaneous Outstanding Shares10,630,000Free Float9,496,000Market Cap$15.63 million OptionableOptionable Beta1.23 Social Links Reduce the RiskMarket downturns give many investors pause, and for good reason. Wondering how to offset this risk? Enter your email address to learn more about using beta to protect your portfolio.Get This Free Report This page (NASDAQ:CTXR) was last updated on 7/30/2025 by MarketBeat.com Staff From Our PartnersAI Frenzy Could Send ‘EarnPhone’ SoaringThe hidden fuel behind AI? Your phone. Billions of data points — from your clicks, swipes, scrolls, and sea...Mode Mobile | SponsoredDrone Company Secures Major Defense Contract Amid Sweeping Policy ShiftOn July 10th, the White House and DoD announced a sweeping new directive to fast-track U.S. drone dominance. ...The Tomorrow Investor | SponsoredYour Bank Account Is No Longer SafeWhat If Washington Declared That: YOUR Money ISN'T Actually Yours? Sounds insane, but that's exactly what ...Priority Gold | SponsoredEx-Hedge Fund Manager Uncovers $100 Trillion Land ShiftTrump's Radical New Plan Could Enrich Thousands This isn't a campaign stunt. It's a $100 trillion move to u...Stansberry Research | SponsoredGenesis 14:13-17 [HIDDEN MEANING?]A mysterious Bible verse from Genesis may hold the key to unlocking what one expert calls an “American birthri...Paradigm Press | SponsoredNvidia’s next AI move could catch traders flat-footedTired of Missing Big AI Moves Like Nvidia? You’re not the problem—your trading system is. Tim’s XGPT system...Timothy Sykes | SponsoredI was wrong about TrumpI made a mistake. A mistake I feel very foolish about. After speaking with Donald Trump and some of his ...Porter & Company | SponsoredOne stock to replace Nvidia"I said 'SELL' before this stock dropped 90%. Today, I'm shouting 'BUY NOW' before it's too late." In 2000,...InvestorPlace | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Citius Pharmaceuticals, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Citius Pharmaceuticals With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.